Beta 1- and beta 2-adrenergic receptor expression in differentiating 3T3-L1 cells. Independent regulation at the level of mRNA.
Regulation of two highly homologous GTP-binding regulatory protein- (G-protein) linked receptors, beta 1- and beta 2-adrenergic receptors, was probed at the level of mRNA in differentiating 3T3-L1 cells. Expression of the two receptor subtypes at the protein level was defined by competition of radioligand binding with CGP-20712A, a highly selective beta 1-adrenergic antagonist. 3T3-L1 fibroblasts express equivalent levels of beta 1- and beta 2-adrenergic receptors. Following treatment with dexamethasone and isobutylmethyl xanthine (IBMX), 3T3-L1 cells differentiate to adipocytes and express 4-fold more receptor, predominantly beta 2-subtype (beta 1-/beta 2- ratio, 5:95). Regulation of beta 1- and beta 2-receptor mRNA levels by differentiation, as well as by steroid alone and IBMX alone was probed by DNA excess solution hybridization. A beta 1-receptor antisense probe was constructed from double-stranded DNA assembled from synthetic oligonucleotides. In untreated 3T3-L1 fibroblasts the steady-state levels of beta 1- and beta 2-adrenergic receptor mRNA were equivalent (approximately 1.2 amol mRNA/micrograms total cellular RNA). beta 2-Adrenergic receptor mRNA levels increased 3-fold as 3T3-L1 fibroblasts were differentiated to adiopcytes (day 7). mRNA levels for beta 1-adrenergic receptor, in contrast, increased at day 2, but thereafter declined, falling to less than 0.05 amol mRNA/micrograms total cellular RNA by day 7 in adipocytes. A 7-day challenge with dexamethasone reduced by 50% beta 1-adrenergic receptor mRNA levels. Treatment with IBMX alone reduced mRNA levels for both receptor subtypes. Neither steroid nor IBMX alone promoted differentiation. The present work, for the first time, demonstrates (i) the mRNA levels on a molar basis for two highly homologous G-protein-linked receptors expressed in a single cell, (ii) independent regulation of their mRNA levels that correlates well with receptor expression, and (iii), that it is differentiation in 3T3-L1 cells per se and not treatment with glucocorticoid or IBMX alone that promotes the up-regulation of the beta 2-receptor transcripts and down-regulation of beta 1-receptor transcripts.
Department of Pharmacology, State University of New York, Stony Brook 11794-8651.
S J
SJ
Guest
J R
JR
Hadcock
D C
DC
Watkins
C C
CC
Malbon
D015056:1-Methyl-3-isobutylxanthine / Q000494:pharmacology; D000273:Adipose Tissue / Q000187:drug effects / Q000378:metabolism; D000319:Adrenergic beta-Antagonists; D001483:Base Sequence; D001667:Binding, Competitive; D002454:Cell Differentiation / Q000187:drug effects; D002460:Cell Line; D015342:DNA Probes; D003907:Dexamethasone / Q000494:pharmacology; D005347:Fibroblasts / Q000378:metabolism*; D005786:Gene Expression Regulation; D007093:Imidazoles / Q000378:metabolism; D008969:Molecular Sequence Data; D009693:Nucleic Acid Hybridization; D012333:RNA, Messenger / Q000235:genetics*; D011943:Receptors, Adrenergic, beta / Q000235:genetics*; D014158:Transcription, Genetic
D000319:Adrenergic beta-Antagonists; D015342:DNA Probes; D007093:Imidazoles; D012333:RNA, Messenger; D011943:Receptors, Adrenergic, beta; D003907:Dexamethasone; C049763:CGP 20712A; D015056:1-Methyl-3-isobutylxanthine